Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Developing therapy for acute ischemic stroke.

M Fisher1

  • 1Department of Neurology, University of Massachusetts Medical School, Worcester, USA. FisherM@ummhc.org

Therapie
|April 2, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ICU admission in patients infected with the human immunodeficiency virus - a multicentre survey.

Anaesthesia·1999
Same author

Novel cationic amphiphiles as delivery agents for antisense oligonucleotides.

Nucleic acids research·1999
Same author

Interventional cardiology in people with diabetes.

Diabetic medicine : a journal of the British Diabetic Association·1999
Same author

Neuroprotective effects of a novel broad-spectrum cation channel blocker, LOE 908 MS, on experimental focal ischemia: a multispectral study.

Journal of magnetic resonance imaging : JMRI·1999
Same author

Transforming growth factor-beta mediates astrocyte-specific regulation of brain endothelial anticoagulant factors.

Stroke·1999
Same author

Endothelin-1 enhances plasminogen activator inhibitor-1 production by human brain endothelial cells via protein kinase C-dependent pathway.

Arteriosclerosis, thrombosis, and vascular biology·1999
Same journal

Pharmacology of pruritus (pathophysiology, therapeutic targets).

Therapie·2026
Same journal

Barriers to prescribing methylphenidate for adults with ADHD: A qualitative study.

Therapie·2026
Same journal

[Self-medication and its factors amongst Navymen aboard surface ships of the French Navy at sea: A descriptive study].

Therapie·2026
Same journal

Subacute cutaneous lupus erythematosus induced by ticagrelor: Recurrence after rechallenge.

Therapie·2026
Same journal

Multiple HIV virological failures related to bictegravir-valproic acid interaction evidenced by therapeutic drug monitoring: A retrospective study.

Therapie·2026
Same journal

Indication-related misuse of oral fluoroquinolones in adults by general practitioners in France.

Therapie·2026
See all related articles

Recombinant tissue-type plasminogen activator (rt-PA) is the only approved acute ischemic stroke treatment, but its use is limited. Future stroke trials may improve success rates with advanced imaging and patient selection.

Area of Science:

  • Neurology
  • Cardiovascular Medicine
  • Medical Imaging

Background:

  • Intravenous recombinant tissue-type plasminogen activator (rt-PA) is the sole approved therapy for acute ischemic stroke, typically administered within 3 hours of symptom onset.
  • Despite its approval, rt-PA is utilized in a small fraction of eligible stroke patients, even at specialized centers.
  • Numerous clinical trials investigating thrombolytic drugs beyond the 3-hour window and neuroprotective agents have yielded negative results.

Purpose of the Study:

  • To review the limitations of current acute ischemic stroke therapies.
  • To identify reasons for the failure of past clinical trials in acute stroke.
  • To propose strategies for improving the success of future acute stroke treatment trials.

Main Methods:

Related Experiment Videos

  • Review of existing literature on acute ischemic stroke treatments and clinical trial outcomes.
  • Analysis of factors contributing to the limited use of rt-PA.
  • Discussion of the potential role of advanced imaging techniques in patient selection for stroke trials.

    • Main Results:

    • The narrow time window for rt-PA administration and patient selection challenges limit its effectiveness.
    • Past trials have faced difficulties in demonstrating efficacy for novel thrombolytic and neuroprotective agents.
    • Advanced imaging, including diffusion/perfusion MRI and CT, offers potential for better patient stratification.

    Conclusions:

    • Improving acute ischemic stroke treatment requires addressing the limitations of current therapies and learning from past trial failures.
    • Enhanced patient selection through advanced imaging technologies is crucial for future trial success.
    • Developing novel therapies for acute stroke remains a critical unmet need, necessitating innovative approaches and rigorous trial design.